Search
Biontech SE
BNTXAdd to Watchlist
96.730USD
+0.330+0.34%
Close 09-11 16:00（ET）
24.32BMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+0.34%
5 Days
-6.78%
1 Month
+5.00%
6 Months
+6.08%
Year to Date
+1.61%
1 Year
-0.01%
Key Figures
96.770Open
97.900High
67.15KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.03%Turnover Ratio
96.400Prev. Close
96.000Low
6.53MTurnover
LossP/E Static
1.19P/B
0.00%Div Yield TTM
-5.93%ROA
124.00052wk High
29.66Volume Ratio
-665.30MNet Profit
251.20MShares
-4.3892EPS TTM
1.33Beta
-6.66%ROE
79.52052wk Low
1.64%Amplitude
24.72%Gross Margin
24.32BMarket Cap
0.52Reward/Risk
2.88%Risk Rate
Recent
Earnings
Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?
• BioNTech and Genentech terminated their Phase 2 autogene cevumeran colorectal cancer trial. • The independent Data Safety Monitoring Board concluded the trial lacked clinical efficacy. • BioNTech reports $3.33B in annual revenue and a net profit of $-1.32B.
TradingKeyFri, Aug 28
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send?
• Povetacicept trial met primary endpoint for kidney disease. • Vertex plans BLA submission by March for accelerated review. • Analysts positive on povetacicept's market potential and stock.
TradingKeyTue, Mar 10
Novo Nordisk A/S Stock (NVO) Moved Down by 3.13% on Mar 10: Facts Behind the Movement
• FDA issued warning letter for adverse drug reporting violations. • Analysts downgraded Novo Nordisk due to pipeline and competition concerns. • Company's 2026 guidance projects sales and profit decline.
TradingKeyTue, Mar 10
Biontech SE's Score
-0.16vs previous score
Forecast7.91
Financial Health7.73
Technical4.51
Valuation Dimensions8.80
Institutional Confidence3.00
Risk Assessment6.24
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Biontech SE Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-3.70/-2.42
Revenue / Forecast
121.75M/182.32M
Biontech SE Profile
SectorBiotechnology & Medical Research
Ticker SymbolBNTX
Number of employees6772
CountryGermany
Ownership
| Shareholders | Proportion |
|---|---|
| AT Impf GmbH | 40.05% |
| Medine GmbH | 15.87% |
| Fidelity Management & Research Company LLC | 2.15% |
| T. Rowe Price Investment Management, Inc. | 1.77% |
| Shareholder Types | Proportion |
|---|---|
| Corporation | 56.27% |
| Investment Advisor | 11.90% |
| Investment Advisor/Hedge Fund | 3.82% |
| Research Firm | 2.02% |
Related Instruments
-0.65%
-0.29%
+0.33%
+0.83%
-0.54%
-0.23%
-1.34%
-0.75%
+0.25%
-2.14%
+0.17%
-0.17%
+0.12%
+0.07%
+0.02%
-1.48%
+0.04%
+0.83%
+5.38%
-0.61%Popular Instruments
52516.000
-37.000 (-0.07%)
28996.600
-372.300 (-1.27%)
7619.400
-37.200 (-0.49%)
14419.000
-37.000 (-0.26%)
63323.000
-1356.000 (-2.10%)
6302.100
-17.700 (-0.28%)
101.343
+2.986 (+3.04%)
332.270
+5.700 (+1.75%)
218.290
-0.070 (-0.03%)
4330.970
-17.080 (-0.39%)
FAQs
What is the current price of Biontech SE (BNTX)?
The current price of Biontech SE (BNTX) is 96.73.
What is the symbol of Biontech SE?
The ticker symbol of Biontech SE is BNTX.
What is the 52-week high of Biontech SE?
The 52-week high of Biontech SE is 124.00.
What is the 52-week low of Biontech SE?
The 52-week low of Biontech SE is 79.52.
What is the market capitalization of Biontech SE?
The market capitalization of Biontech SE is 24.32B.
Is Biontech SE (BNTX) currently rated as Buy, Hold, or Sell?
According to analysts, Biontech SE (BNTX) has an overall rating of Buy, with a price target of 123.70.
What is the Earnings Per Share (EPS TTM) of Biontech SE (BNTX)?
The Earnings Per Share (EPS TTM) of Biontech SE (BNTX) is -4.39.